News
Featured In
August 2023 |
JPEO-CBRND
DOD-Supported Lifesaving Autoinjector to Combat Ultra-Potent Opioid Exposure Available through DLA
September 2022 |
Globe Newswire
Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
September 2022 |
Health.Mil
MHSRS 2022 Award Winner Video: Rapid Opioid Countermeasure System
September 2022 |
JPEO-CBRND
Rapid Opioid Countermeasure System Product Team Wins 2022 Military Health System Research Symposium Award for Outstanding Program Management Team
May 2022 |
JPEO-CBRND
DOD-Supported 10mg Naloxone Autoinjector Receives FDA Approval to Treat Known or Potential Ultra-Potent Opioid Exposure
April 2022 |
HDIAC
DoD-Supported 10-mg Naloxone Autoinjector Receives FDA Approval to Treat Known or Potential Ultra-Potent Opioid Exposure
March 2022 |
Pharmacy Times
FDA Approves 10-mg Naloxone Injection to Treat Exposure to Ultra-Potent Weaponized Opioids
March 2022 |
EMPR.COM
FDA Approves Naloxone Auto-Injector as Countermeasure to High Potency Opioids
June 2021 |
JBSA News
Army Medical Test and Evaluation Activity tests Rapid Opioid Countermeasure System at JBSA-Camp Bullis
June 2021 |
army.mil